

## ASX Release

### EMVISION AWARDED \$5M NON-DILUTIVE GOVERNMENT GRANT

**EMVision Medical Devices Limited (ASX:EMV)** (“EMVision” or the “Company”) is pleased to advise that it has been awarded an Australian Government Industry Growth Program (IGP) Commercialisation and Growth Grant of \$5 million in non-dilutive funding to accelerate the global commercialisation of EMVision’s First Responder portable brain scanner.

EMVision’s CEO Scott Kirkland welcomed the funding support: “Our First Responder portable brain scanner device is a genuine world first product with potential to transform the landscape of pre-hospital stroke and traumatic brain injury care. It is designed to be easily carried to, and operated at the scene, by paramedics and first responders, to enable earlier diagnosis and earlier triage, transfer or treatment decision making. In both stroke and traumatic brain injury, time is a critical determinant of outcome. Quite simply, if we can help save time, we can help save lives and reduce disability.

Clinician and industry feedback on our First Responder device, at home and abroad, has been very encouraging. Having recently returned from engaging with dozens of healthcare professionals across the United States, their feedback is clear - our technology’s advanced development stage and unique value proposition wholly sets it apart in the pre-hospital landscape. To be selected for a highly competitive IGP grant is a strong endorsement of our product’s value proposition and tremendous commercial potential. We are thrilled and appreciative to receive this support from the Department.”



Royal Flying Doctor Service team member pictured with First Responder device (L) and First Responder device overview (R)

A Grant Agreement (“Agreement”) has been executed between EMVision and the Australian Government represented by Department of Industry, Science and Resources. A summary of the Agreement’s key terms and clauses are outlined as an Appendix to this announcement.

## First Responder – Market Access Roadmap



**Aeromedical**

Healthy Volunteer Study  
SUCCESSFUL SCANS COMPLETED

RFDS Usability Study  
ETHICS SUBMITTED



**Mobile Stroke Unit MSU**

Workflow and Data Collection Study  
ETHICS SUBMITTED



**Standard Road Ambulance**

Usability and Workflow Implementation Study  
PROTOCOL PREPARATION

**Clinical Development and Substantial Equivalence Testing**

Demonstration of First Responder performance equivalence or superiority to the emu™ to support FDA 510(k) regulatory clearance.



First Responder

IV



emu





## First Responder Brain Scanner Total Addressable Market



EMVision cautions that there are regulatory barriers and unique access challenges to each market and can be subject to varying rates of penetration. There are further regulatory or market access hurdles to sell to the 'Rest of World', including China, Japan, Brazil, Mexico, South Korea, Spain, Italy, India, and Canada.  
Addressable market estimates are based on ABS, U.S. Census Bureau, WHO, AHA, EMS data and other publicly available data.

Authorised for release by the Board of the Company.

**[ENDS]**

For further information, media or investor enquiries, please contact:

Andrew Keys  
Keys Thomas Associates  
+61 400 400 380  
andrew.keys@keysthomas.com

Sling & Stone  
Media and Communications  
emvision@slingstone.com  
02 8073 5390

Scott Kirkland  
CEO and Managing Director  
+61 2 8667 5337  
skirkland@emvision.com.au

## **APPENDIX: SUMMARY OF AGREEMENT KEY TERMS AND CLAUSES**

- Under the Agreement, grant payments will be paid quarterly in advance, based on forecast eligible expenditure, adjusted for unspent amounts from previous payments. Payments are subject to satisfactory progress on the project against agreed activities. The Industry Growth Program is a matched funding grant program.
- Progress reports will be provided on a quarterly basis with the project anticipated to complete before 22 May 2027.
- The Commonwealth Government may terminate the Agreement if EMVision does not comply with an obligation under the Agreement and the Commonwealth believes that the non-compliance is incapable of remedy, or if EMVision has failed to comply with a notice to remedy, the Commonwealth may by written notice reduce the scope of the Agreement.

### **About EMVision Medical Devices**

EMVision Medical Devices Limited (ASX:EMV) is an innovative Australian medical device company developing a novel approach to looking inside the human body. Our product pipeline includes portable, non-invasive, affordable and safe neurodiagnostic devices.

Our vision is to help transform and improve the timely diagnosis and treatment of stroke and other time sensitive medical emergencies, at the point-of-care.

EMVision has offices in Sydney and Brisbane [www.emvisionmedical.com](http://www.emvisionmedical.com)

### **Forward-looking Statements**

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision's current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

### **Inherent risks of Investment in Medical Device development Companies**

There are a number of inherent risks associated with the development of new medical device products to a marketable stage. The clinical trial process, which is often lengthy, is designed to assess the safety and efficacy of a device prior to commercialisation and there is no guarantee of achieving the outcomes necessary to generate a viable commercial product. Other risks include uncertainty of patent protection and proprietary rights, the obtaining of necessary regulatory authority approvals and the evolving competitive landscape. Companies such as EMVision are dependent on the success of their research and development projects, product development and on the ability to attract funding to support these activities. Investment in research and development and novel product development cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore investment in Companies specialising in such development must be regarded as speculative. EMVision recommends that professional investment advice be sought prior to such investments and cautions investors that the risks of an investment in an entity such as EMVision is not limited to the risks disclosed in this announcement.